FRANKFURT (dpa-AFX) – Following mixed quarterly results and an equally mixed outlook, Fresenius shares are expected to decline again on Wednesday. From a chart analysis perspective, key short- and medium-term trend lines are at risk.
On the Tradegate trading platform, shares of the hospital operator and medical technology company dropped 3.7 percent to 48.50 euros compared to the previous day's Xetra close. This would push the price not only below the 21-day moving average but also below the 50- and 90-day lines, which indicate the medium-term trend.
The day before, Fresenius shares had already been dragged down by weak quarterly figures from dialysis specialist FMC, in which Fresenius still holds a little over 30 percent. The stock had lost 2.6 percent.
A trader commented on the Fresenius 2025 annual figures, highlighting both positives and negatives in the company’s statements regarding revenue, EBIT margin, and earnings per share (EPS). “The projected currency-adjusted revenue growth sounds good, but the anticipated operating profitability falls short of consensus estimates.”
Additionally, the average analyst forecast (consensus) for EPS is already at the upper end of the range provided by Fresenius."/ck/bek/zb
